BIOMAT Database Logo BIOMAT Database Logo

Coagulation factor XII (Hageman factor) Washington D.C.: inactive factor XIIa results from Cys-571----Ser substitution. 1989

T Miyata, and S Kawabata, and S Iwanaga, and I Takahashi, and B Alving, and H Saito
Department of Biology, Faculty of Science, Kyushu University, Fukuoka, Japan.

Structural studies on a congenital abnormal coagulation factor XII (Hageman factor), factor XII Washington D.C., have been performed to identify the defect responsible for its lack of procoagulant activity. Amino acid sequence analysis of a tryptic peptide isolated from the abnormal factor XII indicated that Cys-571 (equivalent to Cys-220 in the chymotrypsin numbering system) had been replaced by serine. No other substitutions in the active-site triad--namely, His-393, Asp-442, and Ser-544--were found. We propose that the Cys-571----Ser replacement found in this factor XII variant destroys the formation of the disulfide linkage between Cys-540 and Cys-571, giving rise to an altered conformation of the active-site serine residue or the secondary substrate-binding site and, thus, leads to the loss of enzyme activity.

UI MeSH Term Description Entries
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D010446 Peptide Fragments Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques. Peptide Fragment,Fragment, Peptide,Fragments, Peptide
D010449 Peptide Mapping Analysis of PEPTIDES that are generated from the digestion or fragmentation of a protein or mixture of PROTEINS, by ELECTROPHORESIS; CHROMATOGRAPHY; or MASS SPECTROMETRY. The resulting peptide fingerprints are analyzed for a variety of purposes including the identification of the proteins in a sample, GENETIC POLYMORPHISMS, patterns of gene expression, and patterns diagnostic for diseases. Fingerprints, Peptide,Peptide Fingerprinting,Protein Fingerprinting,Fingerprints, Protein,Fingerprint, Peptide,Fingerprint, Protein,Fingerprinting, Peptide,Fingerprinting, Protein,Mapping, Peptide,Peptide Fingerprint,Peptide Fingerprints,Protein Fingerprint,Protein Fingerprints
D011487 Protein Conformation The characteristic 3-dimensional shape of a protein, including the secondary, supersecondary (motifs), tertiary (domains) and quaternary structure of the peptide chain. PROTEIN STRUCTURE, QUATERNARY describes the conformation assumed by multimeric proteins (aggregates of more than one polypeptide chain). Conformation, Protein,Conformations, Protein,Protein Conformations
D002851 Chromatography, High Pressure Liquid Liquid chromatographic techniques which feature high inlet pressures, high sensitivity, and high speed. Chromatography, High Performance Liquid,Chromatography, High Speed Liquid,Chromatography, Liquid, High Pressure,HPLC,High Performance Liquid Chromatography,High-Performance Liquid Chromatography,UPLC,Ultra Performance Liquid Chromatography,Chromatography, High-Performance Liquid,High-Performance Liquid Chromatographies,Liquid Chromatography, High-Performance
D003545 Cysteine A thiol-containing non-essential amino acid that is oxidized to form CYSTINE. Cysteine Hydrochloride,Half-Cystine,L-Cysteine,Zinc Cysteinate,Half Cystine,L Cysteine
D005174 Factor XII Stable blood coagulation factor activated by contact with the subendothelial surface of an injured vessel. Along with prekallikrein, it serves as the contact factor that initiates the intrinsic pathway of blood coagulation. Kallikrein activates factor XII to XIIa. Deficiency of factor XII, also called the Hageman trait, leads to increased incidence of thromboembolic disease. Mutations in the gene for factor XII that appear to increase factor XII amidolytic activity are associated with HEREDITARY ANGIOEDEMA TYPE III. Coagulation Factor XII,Hageman Factor,Factor 12,Factor Twelve
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000595 Amino Acid Sequence The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION. Protein Structure, Primary,Amino Acid Sequences,Sequence, Amino Acid,Sequences, Amino Acid,Primary Protein Structure,Primary Protein Structures,Protein Structures, Primary,Structure, Primary Protein,Structures, Primary Protein

Related Publications

T Miyata, and S Kawabata, and S Iwanaga, and I Takahashi, and B Alving, and H Saito
Coagulation factor XIIa (activated Hageman factor) inhibitor from adult Schistosoma mansoni.
March 1977, The American journal of tropical medicine and hygiene,
T Miyata, and S Kawabata, and S Iwanaga, and I Takahashi, and B Alving, and H Saito
Hepatocytes express blood coagulation factor XII (Hageman factor).
April 1990, The Journal of laboratory and clinical medicine,
T Miyata, and S Kawabata, and S Iwanaga, and I Takahashi, and B Alving, and H Saito
Purification and characterization of bovine coagulation factor XII (Hageman factor).
June 1978, European journal of biochemistry,
T Miyata, and S Kawabata, and S Iwanaga, and I Takahashi, and B Alving, and H Saito
cDNA sequence coding for human coagulation factor XII (Hageman).
April 1986, Nucleic acids research,
T Miyata, and S Kawabata, and S Iwanaga, and I Takahashi, and B Alving, and H Saito
[Factor XII (Hageman factor)].
March 1995, Nihon rinsho. Japanese journal of clinical medicine,
T Miyata, and S Kawabata, and S Iwanaga, and I Takahashi, and B Alving, and H Saito
[Factor XII (Hageman factor)].
December 2004, Nihon rinsho. Japanese journal of clinical medicine,
T Miyata, and S Kawabata, and S Iwanaga, and I Takahashi, and B Alving, and H Saito
[Factor XII (HAGEMAN FACTOR)].
January 1978, Folia haematologica (Leipzig, Germany : 1928),
T Miyata, and S Kawabata, and S Iwanaga, and I Takahashi, and B Alving, and H Saito
[Factor XII (Hageman factor)].
September 1999, Nihon rinsho. Japanese journal of clinical medicine,
T Miyata, and S Kawabata, and S Iwanaga, and I Takahashi, and B Alving, and H Saito
Factor XII: Hageman factor.
January 1993, Methods in enzymology,
T Miyata, and S Kawabata, and S Iwanaga, and I Takahashi, and B Alving, and H Saito
Mitogenic effects of coagulation factor XII and factor XIIa on HepG2 cells.
May 1991, Proceedings of the National Academy of Sciences of the United States of America,
Copied contents to your clipboard!